Skip to main navigation Skip to search Skip to main content

HERMES: Effects of Ziltivekimab versus Placebo on Morbidity and Mortality in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Project: Research

Project Details

StatusFinished
Effective start/end date01/11/2403/8/26

Funding

  • Novo Nordisk Incorporated: $27,887.40